This article is more than 5 years old. Information may no longer be current.
Spineart acquires worldwide rights to bone substitute gel
Click Here to Manage Email Alerts
Spineart announced that it has acquired a portfolio of proprietary synthetic orthobiologic solutions from Orthos Ltd, including the worldwide rights to βGel and βGran.
According to a company press release, βGel is an osteoconductive scaffold in the form of a pre-mixed malleable gel. As it reaches body temperature, βGel stiffens and becomes resistant to displacement of body fluids. Its interconnected porosity is controlled to provide a 3-D scaffold that supports vascularization and early cell attachment to function as an osteoconductive template.
A range of high purity synthetic osteoconductive scaffolds intended to be used as bone void fillers in the treatment of osseous defects, βGran is used to treat bone loss resulting from trauma to resolve conduction defects in non-unions and to restore conduction across osteotomy sites. According to the release, βGran has proved effective at expanding the volume of available spinal fusion material as it can be combined with any autograft harvested during the surgical procedure.